Table 1.
Overall | Age | Sex | Race | ||||
---|---|---|---|---|---|---|---|
52–64 y | 65–75 y | Female | Male | White | Black | ||
No. of participants | 11,060 | 6,674 | 4,386 | 6,178 | 4,882 | 8632 | 2428 |
Age (y) | 62.8 ± 5.7 | 58.9 ± 2.6 | 68.8 ±3.2 | 62.5 ± 5.6 | 63.2 ± 5.7*** | 63.1 ± 5.6 | 61.8 ± 5.7*** |
Female sex | 55.8% | 58.1% | 52.5%*** | 100% | 0% | 53.5% | 64.3%*** |
Black race | 22.0% | 24.6% | 17.9%*** | 25.3% | 17.7%*** | 0% | 100% |
History of CVD | 13.9% | 11.2% | 18.0%*** | 10.3% | 18.5%*** | 13.6% | 14.9% |
Current smoker | 14.9% | 16.9% | 11.8%*** | 14.0% | 16.0%*** | 14.0% | 17.7%*** |
Antihypertensive medication | 43.4% | 38.6% | 50.6%*** | 43.6% | 43.1% | 39.0% | 58.8%*** |
Systolic BP (mmHg) | 127.6 ± 19.0 | 124.8 ± 18.1 | 131.8 ± 19.0*** | 128.1 ± 19.6 | 126.9 ± 18.2** | 125.8 ± 18.4 | 133.6 ± 19.9*** |
Diastolic BP (mmHg) | 71.0 ± 10.3 | 72.2 ± 10.1 | 69.2 ± 10.4*** | 70.1 ± 10.3 | 72.2 ± 10.2*** | 69.7 ± 9.9 | 75.8 ± 10.5*** |
Hypertension | 47.4% | 42.0% | 55.5%*** | 49.0% | 45.4%*** | 42.0% | 66.6%*** |
Diabetes | 16.6% | 15.5% | 18.5%*** | 15.6% | 17.9%** | 13.9% | 26.4%*** |
Total Cholesterol (mmol/L) | 5.2 ± 1.0 | 5.2 ± 1.0 | 5.2 ± 0.9 | 5.4 ± 1.0 | 5.0 ± 0.9*** | 5.2 ± 1.0 | 5.2 ± 1.0 |
Body Mass Index (kg/m2) | 28.8 ± 5.6 | 29.1 ± 5.8 | 28.3 ± 5.4*** | 29.1 ± 6.3 | 28.4 ± 4.5*** | 28.3 ± 5.2 | 30.6 ± 6.4*** |
eGFR (mL/min/1.73m2) | 84.1 ± 15.5 | 87.9 ± 14.8 | 78.3 ± 14.8*** | 84.5 ± 15.7 | 83.6 ± 15.2** | 82.6 ± 13.9 | 89.6 ± 19.5*** |
ACR (mg/g) | 3.7 [1.8–7.8] | 3.4 [1.6–6.8] | 4.4* [2.0–10.0] | 4.3 [1.4–7.3] | 3.1 *[2.1–8.3] | 2.7 [0.8–8.9] | 4.0***[2.0–7.7] |
eGFR: estimated glomerular filtration rate; ACR: albumin-creatinine ratio. BP, blood pressure; CVD, cardiovascular disease;
Note: Values for categorical variables are given as percentages; values for continuous variables are given as mean ± standard deviation or median [interquartile range]. p-values were generated by ANOVA or Chi-square test, as appropriate.
p<0.05;
p<0.01;
p<0.001